Meet Our Managing Director
Message
Our Managing Director message in 2nd Anniversary, Dr Gihan Elsisi, ” I feel very privileged to be writing this, we began our journey August 2018, and have spent the past 2 years continuing to build our brand, which has now become synonymous with our commitment to helping our clients expand knowledge and demonstrate the value of innovation in Egypt and Middle East”.
Gihan Hamdy Elsisi
Managing Director, HTA office
Middle East and North Africa
BIO
Gihan Hamdy Elsisi, Msc, PhD is Managing Director, HTA Office LLC, MENA and Lecturer, Faculty of Pharmacy, Future University, Arab Academy for Science and Technology & Cairo University. She is the founder and former Head of Pharmacoeconomic Unit at the Central Administration for Pharmaceutical Affairs (CAPA), Egyptian Ministry of Health and former lecturer at Faculty of Pharmacy, German University in Cairo. Elsisi received PhD in Pharmacoeconomics /pharmaceutical sciences from Ain Shams University and certified in Health Economics (HE) and Outcomes Research, University of Washington. Through the CAPA, Elsisi was able to successfully incorporate Pharmacoeconomics and Outcomes Research into the coverage decisions of drugs. She is the principal author of both Health Care Systems Roadmap for Pharmaceutical pricing and reimbursement and the Pharmacoeconomic Guidelines for Egypt, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). She is an executive member in HE Diploma Committee, American University in Cairo. In 2011 and 2012 she received ISPOR awards at the ISPOR 14th and 15th Annual European Congresses in Madrid and Berlin. Elsisi represented Egypt in the First and Second Middle East Africa Pricing & Reimbursement Future Trends Workshop in Muscat 2012 and in Dubai 2013. She has several publications in HE and also contributed to a number of clinical research and surveys. She is the treasurer of ISPOR Egypt Chapter. She is a special guest speaker at many international companies for achieving market access and maximizing commercial performance in Turkey & Middle East.